[VIDEO] Voices of Choice - Lucio from Rio de Janeiro Discusses Being in the iPrEx Open Label PrEP Trial

In the video below, Lucio from Rio discusses his participation in the iPrEx Open Label Study and taking Truvada as a way to prevent HIV infection.

The iPrEx trial was the first study to show that an antiretroviral drug (ARV) - normally used to treat people living with HIV - could also be used to prevent HIV among people who are HIV-negative.

In July of 2012, the FDA approved the ARV drug Truvada for the prevention of HIV.

RESEARCH OPPORTUNITY FOR YOUNG GAY MEN IN THE U.S. 

Are you a young gay man living in the United States between the ages of 15 and 17? Are you interested in new methods of preventing HIV, like PrEP?

Project PrEPare is an innovative HIV prevention study designed to explore the safety, acceptability and feasibility of PrEP among young  gay men and other men who have sex with men who are at risk for HIV infection in the United States.

The study is taking place at clinical sites across the U.S. in Los Angeles, Philadelphia, Chicago, New Orleans, Boston and Denver. Click here to quickly check if you are eligible to participate.

More information about the study and city-specific contact information can be found on the Project PrEPare website.